SleepUp Digital CBTi-based Platform for Insomnia

February 1, 2024 updated by: SleepUp Tecnologia em Saúde Ltda

Evaluation of SleepUp Digital CBTi-based Platform in the Treatment of Insomnia

Cognitive-Behavioral Therapy for insomnia (CBTi) is a well-established therapeutic intervention for insomnia. SleepUp provides a digital therapeutics platform based on CBTi and additional features. This clinical trial aims at analyzing the efficacy of the CBTi-based platform offered by SleepUp in reducing symptoms of insomnia.

The sample will be composed of 160 individuals, both males and females, from 20 to 60 years old, with insomnia symptoms considered as at least mild. Those who accept to participate will be randomized and distributed in four groups:

  • Standard CBTi (CBTi-S): This treatment consists of an eight-week treatment composed by weekly and structure appointments with board-certified sleep psychologists. The appointments will be made remotely (video calls with psychologists).
  • Minimal intervention - Sleep hygiene (MI-SH): This group informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no treatment or waiting list controls, due to the behavioral nature of insomnia.
  • Online CBTI (CBTI-O): This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
  • Online CBTi + additional features (CBTi-O+): This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.

All participants in all groups will be assessed periodically throughout the eight weeks of intervention with standard sleep questionnaires and sleep logs. Additionally, follow ups will be made at two, four and six months after the end of the intervention. Equivalent intervals will be applied to the SH-MI group.

Study Overview

Detailed Description

Cognitive-Behavioral Therapy for insomnia (CBTi) is a well-established therapeutic intervention for insomnia. In its standard presentation, it is composed by 6 to 12 weekly appointments with a board-certified sleep psychologist. SleepUp provides a digital therapeutics platform based on CBTi and additional features. This clinical trial aims at analyzing the efficacy of the CBTi-based platform offered by SleepUp in reducing symptoms of insomnia.

The participants will be recruited based on SleepUp's records and database and invited to participate. Those participants who are eligible in accordance to the inclusion and exclusion criteria will be contact by a member of the research team who will provide a consent form and will explain the terms and conditions of this research project. The sample will be composed of 160 individuals, both males and females, from 20 to 60 years old, with insomnia symptoms considered as at least mild, according to the Insomnia Severity Index (ISI). All groups shall have similar proportions of gender and of insomnia symptoms severity. Those who accepted to participate will be randomized and distributed in four groups:

  • Standard CBTi (CBTi-S): This is a positive control group, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structure appointments with psychologists. Only psychologists board-certified in sleep medicine will perform the CBTi sessions, and none of them are part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
  • Minimal intervention - Sleep hygiene (MI-SH): This group corresponds to a negative control group, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no treatment or waiting list controls, due to the behavioral nature of insomnia.
  • Online CBTI (CBTI-O): This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
  • Online CBTi + additional features (CBTi-O+): This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.

All participants in all groups will be assessed periodically throughout the eight weeks of intervention. Additionally, follow ups will be made at two, four and six months after the end of the intervention. Equivalent intervals will be applied to the SH-MI group. The following clinical questionnaires and scales will be used:

  • Sleep log: It includes self-reported items regarding wake and bedtime, sleep latency and other sleeping habits. It allows the calculation of total sleep time, sleep efficiency and wake time after sleep onset. Fille daily.
  • Morningness and Eveningness Questionnaire: It evaluates chronotype based on 19 items, allowing categorizing the participants according to the following categories: morning type (definitive or moderate), intermediate, or evening type (definitive or moderate). Applied once, in the first week of follow up.
  • Insomnia Severity Index: It evaluates the presence and severity of insomnia, categorizing the participants according to the following categories: no, mild, moderate or severe insomnia. Applied once every two weeks.
  • Epworth Sleepiness Scale: It evaluates excessive daytime sleepiness by inquiring about the chance of sleeping in eight daily situations. Scores higher than 10 indicates excessive daytime sleepiness. Applied once every two weeks.
  • Pittsburgh Sleep Quality Index: It evaluates overall sleep quality based on 19 self-reported items. Scores higher than 5 indicates poor sleep quality. Applied once every two weeks.
  • Sleep Hygiene Index: It habits related to sleep hygiene, based on 13 self-reported items.

Study Type

Interventional

Enrollment (Estimated)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • São Paulo
      • São Caetano Do Sul, São Paulo, Brazil, 09530-250
        • SleepUp Tecnologia em Saúde LTDA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Literate Brazilian portuguese speakers.
  • Insomnia symptoms (as measured by ISI).
  • An Android-based smartphone or tablet with access to the Internet.

Exclusion Criteria:

  • Previous experience with CBTi.
  • Use of sleeping pills or any other treatment for insomnia for two or more days a week in the last three months.
  • Presence of self-reported co-morbidities (hypertension, hyper/hypothyroidism, asthma, bronquitis or other respiratory diseases, rhinitis, epilepsy and other neurological diseases, any psychiatric disease other than depression and anxiety, diabetes) or sleep disoders other than insomnia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard CBTi (CBTi-S):
This is a positive control group/active comparator, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structured appointments with a board-certified sleep psychologist. The professionals performing the CBTi sessions will not be part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
Placebo Comparator: Minimal intervention - Sleep hygiene (MI-SH):
This group corresponds to a negative control group/placebo comparator, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no-treatment or waiting list controls, due to the behavioral nature of insomnia.
It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by regular mail and email.
Experimental: Online CBTI (CBTI-O)
This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
Experimental: Online CBTi + additional features (CBTi-O+)
This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.
The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to the treatment
Time Frame: On the completion of the intervention (average: 8 weeks)
It will be measured as the percentage of participants who completed the treatment, out of those who effectively initiated it. Dropouts will be considered whenever a participants fail to comply with the tasks relative to each group for two consecutive weeks, or postpone the completion of these tasks for three times. These tasks refer to the responses to periodic questionnaires and to the completion of the CBTi or CBTi-O sessions (when applicable).The aim of this comparison is to evaluate whether the adherence rate in the CBTi-O and CBTi-O+ groups are similar to the standard treatment (CBTi-S) or higher than the minimal treatment (SL-MI).
On the completion of the intervention (average: 8 weeks)
Response to treatment
Time Frame: On the baseline and on the completion of the intervention (average: 8 weeks)
Patients are considered to be responsive to treatment if the ISI score is at least 7 points lower than on the basal evaluation.
On the baseline and on the completion of the intervention (average: 8 weeks)
Remission of symptoms
Time Frame: On the completion of the intervention (average: 8 weeks)
Patients are considered to be with no symptoms of insomnia if the ISI score is lower then 8.
On the completion of the intervention (average: 8 weeks)
Maintenance of results
Time Frame: 6 months after the end of the treatment.
Among those patients who completed the treatment program, maintenance of results will be calculated based on the same metrics of "response to treatment" and "remission of symptoms".
6 months after the end of the treatment.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to the treatment
Time Frame: 2 weeks after the beginning of the intervention.
It will be measured as the percentage of participants who completed the treatment, out of those who effectively initiated it. Dropouts will be considered whenever a participants fail to comply with the tasks relative to each group for two consecutive weeks, or postpone the completion of these tasks for three times. These tasks refer to the responses to periodic questionnaires and to the completion of the CBTi or CBTi-O sessions (when applicable).The aim of this comparison is to evaluate whether the adherence rate in the CBTi-O and CBTi-O+ groups are similar to the standard treatment (CBTi-S) or higher than the minimal treatment (SL-MI).
2 weeks after the beginning of the intervention.
Adherence to the treatment
Time Frame: 4 weeks after the beginning of the intervention.
It will be measured as the percentage of participants who completed the treatment, out of those who effectively initiated it. Dropouts will be considered whenever a participants fail to comply with the tasks relative to each group for two consecutive weeks, or postpone the completion of these tasks for three times. These tasks refer to the responses to periodic questionnaires and to the completion of the CBTi or CBTi-O sessions (when applicable).The aim of this comparison is to evaluate whether the adherence rate in the CBTi-O and CBTi-O+ groups are similar to the standard treatment (CBTi-S) or higher than the minimal treatment (SL-MI).
4 weeks after the beginning of the intervention.
Adherence to the treatment
Time Frame: 6 weeks after the beginning of the intervention.
It will be measured as the percentage of participants who completed the treatment, out of those who effectively initiated it. Dropouts will be considered whenever a participants fail to comply with the tasks relative to each group for two consecutive weeks, or postpone the completion of these tasks for three times. These tasks refer to the responses to periodic questionnaires and to the completion of the CBTi or CBTi-O sessions (when applicable).The aim of this comparison is to evaluate whether the adherence rate in the CBTi-O and CBTi-O+ groups are similar to the standard treatment (CBTi-S) or higher than the minimal treatment (SL-MI).
6 weeks after the beginning of the intervention.
Response to treatment
Time Frame: On the baseline and 2 weeks after the beginning of the intervention.
Patients are considered to be responsive to treatment if the ISI score is at least 7 points lower than on the basal evaluation.
On the baseline and 2 weeks after the beginning of the intervention.
Response to treatment
Time Frame: On the baseline and 4 weeks after the beginning of the intervention.
Patients are considered to be responsive to treatment if the ISI score is at least 7 points lower than on the basal evaluation.
On the baseline and 4 weeks after the beginning of the intervention.
Response to treatment
Time Frame: On the baseline and 6 weeks after the beginning of the intervention.
Patients are considered to be responsive to treatment if the ISI score is at least 7 points lower than on the basal evaluation.
On the baseline and 6 weeks after the beginning of the intervention.
Remission of symptoms
Time Frame: 2 weeks after the beginning of the intervention.
Patients are considered to be with no symptoms of insomnia if the ISI score is lower then 8.
2 weeks after the beginning of the intervention.
Remission of symptoms
Time Frame: 4 weeks after the beginning of the intervention.
Patients are considered to be with no symptoms of insomnia if the ISI score is lower then 8.
4 weeks after the beginning of the intervention.
Remission of symptoms
Time Frame: 6 weeks after the beginning of the intervention.
Patients are considered to be with no symptoms of insomnia if the ISI score is lower then 8.
6 weeks after the beginning of the intervention.
Maintenance of results
Time Frame: 2 months after the end of the treatment.
Among those patients who completed the treatment program, maintenance of results will be calculated based on the same metrics of "response to treatment" and "remission of symptoms".
2 months after the end of the treatment.
Maintenance of results
Time Frame: 4 months after the end of the treatment.
Among those patients who completed the treatment program, maintenance of results will be calculated based on the same metrics of "response to treatment" and "remission of symptoms".
4 months after the end of the treatment.
Sleep quality
Time Frame: 2 weeks after the beginning of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
2 weeks after the beginning of the treatment
Sleep quality
Time Frame: 4 weeks after the beginning of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
4 weeks after the beginning of the treatment
Sleep quality
Time Frame: 6 weeks after the beginning of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
6 weeks after the beginning of the treatment
Sleep quality
Time Frame: On the completion of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
On the completion of the treatment
Sleep quality
Time Frame: 2 months after the end of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
2 months after the end of the treatment
Sleep quality
Time Frame: 4 months after the end of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
4 months after the end of the treatment
Sleep quality
Time Frame: 6 months after the end of the treatment
Sleep quality will be measured by the Pittsburgh Sleep Quality Index
6 months after the end of the treatment
Sleep hygiene
Time Frame: 2 weeks after the beginning of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
2 weeks after the beginning of the treatment
Sleep hygiene
Time Frame: 4 weeks after the beginning of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
4 weeks after the beginning of the treatment
Sleep hygiene
Time Frame: 6 weeks after the beginning of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
6 weeks after the beginning of the treatment
Sleep hygiene
Time Frame: On the completion of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
On the completion of the treatment
Sleep hygiene
Time Frame: 2 months after the end of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
2 months after the end of the treatment
Sleep hygiene
Time Frame: 4 months after the end of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
4 months after the end of the treatment
Sleep hygiene
Time Frame: 6 months after the end of the treatment
Sleep hygiene habits will be measured by the Sleep Hygiene Index
6 months after the end of the treatment
Excessive daytime sleepiness
Time Frame: 2 weeks after the beginning of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
2 weeks after the beginning of the treatment
Excessive daytime sleepiness
Time Frame: 4 weeks after the beginning of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
4 weeks after the beginning of the treatment
Excessive daytime sleepiness
Time Frame: 6 weeks after the beginning of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
6 weeks after the beginning of the treatment
Excessive daytime sleepiness
Time Frame: On the completion of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
On the completion of the treatment
Excessive daytime sleepiness
Time Frame: 2 months after the end of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
2 months after the end of the treatment
Excessive daytime sleepiness
Time Frame: 4 months after the end of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
4 months after the end of the treatment
Excessive daytime sleepiness
Time Frame: 6 months after the end of the treatment
Excessive daytime sleepiness will be measured using the Epworth Sleepiness Scale
6 months after the end of the treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gabriel Pires, PhD, Instituto do Sono

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2022

Primary Completion (Estimated)

May 1, 2024

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

June 13, 2021

First Submitted That Met QC Criteria

June 24, 2021

First Posted (Actual)

July 2, 2021

Study Record Updates

Last Update Posted (Estimated)

February 5, 2024

Last Update Submitted That Met QC Criteria

February 1, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • SleepUp_#01
  • 34113520.1.0000.5494 (Other Identifier: Brazilian National Comission of Research Ethics)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep Disorder

Clinical Trials on Regular Cognitive Behavioural Therapy for Insomnia

3
Subscribe